Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Adherium Ltd. ( (AU:ADR) ) has provided an update.
Adherium has surpassed its key calendar year 2025 shipment targets for its Hailie Smartinhaler platform, delivering more than 2,034 devices to Remote Patient Monitoring (RPM) patients and exceeding 4,666 total devices across all channels, ahead of its 2,000 RPM and 4,000 total patient shipment goals. The RPM channel is emerging as the main engine of near-term growth, giving Adherium direct patient relationships, recurring reimbursed revenue, and a scalable operational base that both underpins its confidence in meeting future patient targets, including 10,000 active RPM patients by the end of 2026, and strengthens its positioning to secure larger value-based care agreements with US insurers and expand into broader patient populations.
The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.
More about Adherium Ltd.
Adherium Limited is an Australian-based global leader in digital respiratory management and the developer of the US FDA-cleared Hailie Smartinhaler platform. The company focuses on connected inhaler devices and remote patient monitoring solutions, targeting respiratory patients and healthcare providers with technology that supports adherence, clinical oversight, and value-based care models, particularly in the US market.
Technical Sentiment Signal: Sell
Current Market Cap: A$7.53M
For detailed information about ADR stock, go to TipRanks’ Stock Analysis page.